InRAD
The International Registry of Alzheimer’s Disease and Other Dementias (InRAD): an international observational study dedicated to the evaluation of outcomes data in Alzheimer’s disease.
Project Description
The International Registry of Alzheimer’s Disease and Other Dementias (InRAD) is an international, longitudinal, observational study dedicated to the collection and analysis of clinical data on people with Alzheimer’s disease (AD) under routine clinical practice conditions.
The study invites psychiatrists, geriatricians, neurologists, and other specialists in neurodegenerative diseases affecting cognition and function, as well as their healthcare centers and clinical teams worldwide, to participate.
Study Purpose
The primary objective of the study is to advance epidemiological and outcomes research through an international registry based on a standardized minimum clinical dataset.
To this end, the InRAD Registry collects pseudonymized demographic and clinical data from patients with Alzheimer’s disease who have provided informed consent, enabling the combination, comparison, and analysis of information from multiple centers and countries.
The InRAD Registry
The InRAD Registry is a web-based research registry that enables the collection, integration, comparison, and analysis of pseudonymized demographic and clinical data from patients with Alzheimer’s disease who have provided informed consent.
Participating centers share pseudonymized datasets through the InRAD data entry system. This software tool is designed to provide real-time support to healthcare professionals during the care of people with Alzheimer’s disease and should not be confused with hospital Electronic Medical Records (EMRs).
Research Areas
The study evaluates the long-term progression of Alzheimer’s disease under real-world clinical practice conditions.
The areas of investigation include:
- progression through the different stages of the disease;
- cognitive and functional changes over time;
- the relationship between demographic characteristics and clinical outcomes;
- the impact of comorbidities;
- the results of diagnostic and follow-up assessments;
- exposure to pharmacological treatments;
- associated clinical outcomes.
Data are analyzed using a range of statistical methods to minimize indication bias and other potential sources of confounding.
Specific Objectives
In addition, the study aims to:
- Compare demographic characteristics, disease progression, and clinical outcomes across different countries and regions.
- Analyze how these variables evolve over time.
- Characterize the occurrence of medical events, including adverse events (AEs) and serious adverse events (SAEs), in patients treated with Alzheimer’s disease-specific therapies.
- Evaluate the relationship between these events, treatment exposure, and treatment sequencing.
